Reported 2 days ago
Johnson & Johnson (JNJ) has been highlighted as one of the top innovative healthcare stocks to monitor in 2025, standing out in a sector facing rising costs due to Medicare and tariff impacts from China. With strong financials showing a 4.3% sales increase to $88.8 billion in 2024, JNJ's strategic acquisition of IntraCellular aims to enhance its neurological product portfolio. While it ranks 4th among innovative stocks, analysts suggest that AI stocks may offer even greater potential for returns.
Source: YAHOO